Hasil Pencarian  ::  Simpan CSV :: Kembali

"[Tujuan: Mengidentifikasi korelasi dan insiden metastasis tulang pada pasien kanker prostat dengan Gleason Score (GS) dan Prostate Specific Antigen (PSA) yang rendah.Material dan Metode: Studi deskriptif retrospektif pada pasien kanker prostat di Rumah Sakit Cipto Mangunkusumo periode 2006-2011. Ada 478 pasien dengan kanker prostat. Pasien kanker prostat dengan PSA rendah, telah menjalani pemeriksaan histopatologi, dan bone scan diikutsertakan dalam studi, sehingga didapatkan 358 pasien sebagai subjek penelitian.Nilai PSA diukur dengan sandwich electrochemiluminescent immunoassay. Pemeriksaan histopatologi diklasifikasikan menurut sistem grading Gleason dan dibagi menjadi 3 kategori: diferensiasi baik (GS ≤6), diferensiasi sedang (GS 7), dan diferensiasi buruk (GS 8-10). Bone scan dikerjakan dengan dengan agen radiofarmaka (Tc99m methylenendiphosphonate) dan kemudian gambar ditangkap dengan kamera gamma.Hasil: Rerata usia 67.52±7.8 tahun, rerata GS 7.7±1.3, dan median PSA adalah 56.9 (rentang: 0,48-17000 ng/mL). Ada 11 orang pasien (3,0%) dengan bone scan positif dengan PSA <20 ng/mL dan GS<8. Lebih lanjut, ada 2 pasien (0,6%) dengan GS≤6 dan PSA<10 ng/mL memperlihatkan metastasis ke tulang.Kesimpulan: Pada studi ini, ada sebagian kecil pasien mengalami metastasis tulang dengan PSA (PSA<10 mg/mL) dan GS (GS≤6) rendah., Objective This study was aimed to identify correlation and incidence of bone metastases in prostate cancer patient with low Gleason Score GS and Prostate Specific Antigen PSA Materials and Methods A descriptive restrospective study to patients with prostate cancer in Cipto Mangunkusumo Hospital in 2006 2011 There were 478 patient with prostate cancer Patients with prostate cancer who had PSA value histological examination and bone scan were included in the study resulting in 358 eligible patients for the study PSA value was measured using the sandwich electrochemiluminescent immunoassay Histological examination was graded according to Gleason rsquo s grading system and divided into 3 category well differentiated GS le 6 moderately differentiated GS 7 and poorly differentiated GS 8 10 Bone scan was done using radiopharmaceuticals agent Tc 99m methylenen diphosphonate and then the image was captured using gamma camera Results The mean age was 67 52 7 8 mean GS was 7 7 1 3 and median PSA was 56 9 range 0 48 17000 ng mL There were 11 patients 3 0 with positive bone scan with PSA]"

"[ABSTRAKTujuan: Insiden kanker prostat secara global terus meningkat. Meskipun dapat dilakukan deteksi dini kanker prostat, perlu dipahami bahwa progresivitas penyakit ? menjadi metastasis ? berbeda untuk setiap pasien. Penelitian ini bertujuan untuk mengamati aspek-aspek yang mungkin berperan sebagai faktor prediktif metastasis pada kanker prostat tidak terpalpasi.Material dan Metode: Data dikumpulkan dari Rumah Sakit Umum Pusat Nasional Cipto Mangunkusumo dan Rumah Sakit Pusat Kanker Nasional Dharmais sejak tahun 1995-2013. Pasien dengan kanker prostat tidak terpalpasi kemudian dibagi menjadi dua kelompok: dengan metastasis dan tanpa metastasis. Usia, volume prostat, nilai prostate-spesific antigen (PSA), Gleason score sum group, stadium tumor, Karnofsky performance score (KPS), kadar hemoglobin, dan kadar kreatinin serum merupakan faktor yang dianalisis dalam penelitian ini. Data dianalisis menggunakan analisis bivariat dan uji regresi logistik. Hanya pasien dengan data lengkap yang dimasukkan dalam penelitian ini.Hasil: Didapatkan 91 pasien dengan data lengkap, 59 pasien (64,83%) tanpa metastasis dan 32 pasien (35,16%) dengan metastasis. Terdapat perbedaan statistik yang signifikan antara kelompok tanpa metastasis dan kelompok dengan metastasis, yakni untuk PSA (13.7ng / mL vs 71.5ng / mL; p = 0,001), kadar hemoglobin (13,60 g / dL vs 12,25 g / dL; p = 0,002), dan KPS (90 vs 90 ; p = 0,004). Perbedaan yang signifikan secara statistik juga didapatkan pada kelompok GSS (35 dan 24 pada kelompok tanpa metastasis vs 12 dan 20 pada kelompok dengan metastasis; p = 0,047). Usia, volume prostat, stadium tumor, dan kadar kreatinin antara kedua kelompok tidak memiliki perbedaan signifikan secara statistik (p> 0,05). Nilai pretreatment PSA adalah satu-satunya faktor prediktif untuk metastasis dengan odds ratio 1.014 (95% CI, 1,005-1,022; p = 0,002).Kesimpulan: Sebagian besar pasien kanker prostat tidak terpalpasi terdeteksi pertama kali tanpa metastasis. Nilai pretreatment PSA yang diperoleh pada kunjungan awal pasien dapat digunakan sebagai faktor prediktif metastasis di masa depan.

---

ABSTRACTObjective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.;Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.;Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.;Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.;Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future., Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.]"

"ABSTRAKTujuan: Mengetahui batasan nilai PSA untuk memprediksi adanya metastasis tulang pada pasien kanker prostat di RS Sardjito. Metode: Penelitian retrospektif, dengan mengumpulkan rekam medis pasien kanker prostat telah dilakukan bone scintigraphy di RS Sardjito tahun 2006 - 2011.Hasil: Dari 83 pasien kanker prostat yang telah dilakukan bone scintigraphy, terdapat 55 pasien (66%) mengalami metastasis tulang dan terdapat 28 pasien (34 %) yang tidak mengalami metastasis tulang. Dari 55 pasien yang mengalami metastasis tulang, terdapat 11 pasien (20 %) dengan PSA kurang dari 20 ng/ml dan terdapat 44 pasien (80 %) yang memiliki PSA lebih dari 20 ng/ml. Cut-off point PSA 17.65 ng/ml memiliki sensitivitas terbesar yaitu 85.5% dan spesifisitas 53.6%.Kesimpulan: Pemeriksaan bone scintigraphy dianjurkan pada pasien dengan PSA > 17.65 ng/ml, sedangkan pada pasien dengan PSA < 17.65 dianjurkan pada pasien dengan gejala klinis nyeri tulang.

---

ABSTRACTObjective: Prostate cancer shows a strong predilection to spread to the bones, with bone metastases identified at autopsy in up to 90 % of patients dying from prostate cancer. Serum prostate specific antigen (PSA) concentration has been widely applied as a biomarker to diagnose and monitor prostate cancer. Technetium-99m methylene diphosphate (Tc—99m MDP) whole body bone scintigraphy is currently a well-accepted diagnostic procedure for bone metastasis in malignancy. The aim of this study was to establish a useful serum PSA cut-off value to predict the presence of bone metastasis in men with prostate cancer. Material and Methods: Consecutive male patients diagnosed with prostate cancer were retrospectively analyzed. All of the subjects had received Tc-99m MDP whole body bone scintigraphy and had their serum PSA concentration measured at Sardjito Hospital, Yogyakarta. The proper cut-off value was established based on statistical analysis in order to predict the possibility of bone metastasis among prostate cancer patients.Results: In total, 83 consecutive male patients with prostate cancer were enrolled, and 55 patients (66 %) were confirmed by scintigraphic findings to have bone metastases. A serum PSA concentration of 17,65 ng/ml gave the best sensitivity (78,33 %) and specificity (65,21 %). The positive predictive value, negative predictive value were 85,45 % and 53,57 %, respectively (p<0,05).Conclusion: A cut-off value of 17,65 ng/ml appears to be an appropriate benchmark for stratifying metastatic bone disease in prostate cancer patients at Sardjito Hospital, Yogyakarta, such that if a patient with newly diagnosed prostate cancer and without any skeletal symptoms has a serum PSA concentration of less than 17,65 ng/ml,we suggest that they would not need to undergo bone scintigraphy."

"[Pendahuluan: Sejak tahun 70-an hingga sekarang, skor Gleason merupakan parameter penting pada penatalaksanaan kanker prostat. Biopsi prostat yang umum dipakai untuk membedakan antara kondisi jinak dan ganas semakin menjadikan skor Gleason berperan penting dalam menentukan tatalaksana selanjutnya. Meskipun demikian, terdapat diskrepansi antara skor Gleason yang diambil secara biopsi dan paskaoperasi.Tujuan: Untuk menentukan perbedaan skor Gleason sebelum dan setelah dilakukan prostatektomi radikal, dan untuk mencari faktor-faktor yang berperan dalam peningkatan skor Gleason.Metode: Dilakukan evaluasi laporan patologi dari spesimen prostat yang didapatkan secara biopsi dan paska prostatektomi radikal antara Januari 2004 sampai Desember 2013. Kriteria eksklusi dari studi ini adalah laporan-laporan yang tidak mencantumkan skor Gleason ataupun diagnosis selain adenokarsinoma prostat.Hasil: Studi ini menginklusikan 36 subjek dengan adenokarsinoma prostat yang telah menjalani prostatektomi radikal. Skor Gleason 6 merupakan skor tersering yang dilaporkan pada biopsi, sedangkan skor Gleason 7 merupakan skor tersering yang dilaporkan pada spesimen prostatektomi radikal. Diantara subjek, 58,3% (n=21) memiliki perbedaan antara skor Gleason biopsi dan prostatektomi radikal; 11,1% (n=4) memiliki penurunan dan 47,2% (n=17) mengalami peningkatan. Dengan menggunakan analisis statistik dijumpai bahwa rendahnya densitas PSA (PSAD) memiliki korelasi dengan likelihood peningkatan (r=0,658, p=0,006).Kesimpulan: Sebagian besar pasien memiliki perbedaan antara skor Gleason hasil biopsi dan paskaoperasi dimana terlihat kecenderungan peningkatan dibandingkan dengan penurunan skor. PSAD merupakan faktor yang berkorelasi dengan peningkatan skor Gleason., Introduction: Since its introduction in mid 70 until now, Gleason Score is an important parameter in the treatment of prostate cancer. The common practice of prostate biopsy to differentiate between malignant and benign condition of the prostate, hence makes Gleason score plays important role in determine the next step of treatment. Still there is a discrepancy between Gleason score taken from biopsy and postoperatively.Aim: To determine the Gleason score difference before and after radical prostatectomy, and to find factors that has a role in the upgrading of Gleason score.Methods: We evaluated pathology reports of prostate specimens obtained from biopsy and after radical prostatectomy between January 2004 until December 2013. Exclusion criteria of this study were reports that failed to mentioned Gleason score or a diagnosis apart from adenocarcinoma of the prostate.Results: This study enrolled 36 subjects with adenocarcinoma of the prostate who underwent radical prostatectomy. Gleason score 6 was the most reported score in initial biopsy while Gleason score 7 was the most reported in radical prostatectomy specimen. Among the subjects 58.3% (n=21) had diferrences of Gleason score between biopsy and radical proistatectomy; 11.1% (n=4) had a downgrading and 47.2% (n=17) had an upgrading. Using statistical analysis we found out that low prostate specific antigen densities (PSAD) had correlation with upgrading likelihood (r 0.658, p = 0.006)Conclusion: More than half of our patient had differences between biopsy Gleason score and postoperative scores with majority showed a likelihood of upgrading rather than downgrading, PSAD was the factors that correlates with upgrading in Gleason score.]"

"ABSTRAKPendahuluan : Docetaxel telah menunjukkan efek dalam pengobatan CRPC biladigunakan sebagai monoterapi atau dalam kombinasi dengan kemoterapi lainnya.Banyak penelitian telah menunjukkan korelasi penurunan Prostate Specific Antigen PSA dengan kesintasan pasien CRPC yang mendapatkan terapi Docetaxel.Penelitian-penelitian sebelumnya juga menyatakan adanya korelasi antara volumeprostat, Gleason Score, dan insiden metastasis dengan nilai PSA. Penelitian inibertujuan untuk menganalisis hubungan antara volume prostat, Gleason Score, danada tidaknya metastasis terhadap penurunan PSA sebagai prediktor respon padapasien CRPC yang mendapatkan Docetaxel.Metode : Penelitian analitik retrospektif dengan mengunakan data rekam medisRumah Sakit Umum H. Adam Malik Medan yang dilaksanakan pada periode 1Januari 2016-31 Juli 2016. Populasi dan sampel dalam penelitian ini adalah seluruhpasien dengan penderita CRPC yang telah menjalani kemoterapi Docetaxelsebanyak 10 siklus. Pasien yang memenuhi kriteria inklusi, dipaparkan denganvariabel independen Taksiran Besar Prostat, Skor Gleason, Status Metastase danvariabel dependen perubahan PSA .Hasil : Sebanyak 8 pasien yang memenuhi kriteria inklusi yang berusia rata-rata 65tahun dengan taksiran berat prostat 38,6 gram dengan skor gleason ge; 7 sebanyak 6orang 75 sedangkan

---

ABSTRACTIntroduction Docetaxel has shown efficacy in CRPC treatment as monotherapy or combination therapy. Previous research showed a correlation between prostat volume, Gleason score, and metastases with PSA value. This study aimed toanalyze the correlation between prostat volume, gleason score, and metastases withPSA value decrement as a response predictor in CRPC patients who receiveDocetaxel.Methods This is a retrospective analytic research, using data in medical recordsin RSU H. Adam Malik Medan, conducted on January 1 July 31 2016. Populationand samples in this research are patients with CRPC who already received 10 cyclesof Docetaxel chemotherapy. Patients that fulfilled the inclusion criteria areanalyzed with dependent and independent variables estimated prostate volume,Gleason Score, and metastatic status . Results Total of 8 patients who fulfilled inclusion criteria were averagely 65 yearsold, estimated prostate weight of 38.6 gram, and 6 people had Gleason score ge 7 75 and 2 people had Gleason score "

"Kanker prostat adalah angka kematian terkait kanker tertinggi kedua pada pria setelahkanker paru-paru. Neutrophyl to lymphocyte ratio (NLR), salah satu parameterinflamasi, ditemukan sebagai faktor prognostik pada beberapa jenis tumor padat,seperti kanker prostat. Penelitian ini bertujuan untuk menilai ada tidaknya hubunganantara NLR dengan hasil skor Gleason pasien biopsi adenokarsinoma prostat di RSUDHaji Adam Malik Medan. Sebanyak 121 pasien menjalani biopsi prostat dari awalJanuari 2013 - Desember 2015 di RS Adam Malik dan 30 tidak dikeluarkan. Data dari91 pasien kemudian diambil meliputi umur, data hematologi pra biopsi, pemeriksaanPSA awal, estimasi berat prostat, dan skor gleason dari hasil biopsi. Data diolah denganSPSS versi 22. Ditemukan pasien dengan usia rata-rata 68,34 tahun dengan rentang usia52-85 tahun. Tidak ada hubungan bermakna antara NLR dan TBP dengan r = 0,077 danp = 0,469 serta tidak ada hubungan bermakna antara NLR dan PSA dengan r = 0,072dan p = 0,496. Ada hubungan yang signifikan antara rasio neutrofil / limfosit denganhasil pemeriksaan gleason score pada pasien kanker prostat di RSUP Haji Adam Malik.Diperlukan penelitian lebih lanjut, apakah rasio neutrofil / limfosit dapat digunakanuntuk memprediksi skor gleason score pada pasien suspek kanker prostat

---

Prostate cancer is the second highest cancer-related mortality rate in men after lung

cancer. Neutrophyl to lymphocyte ratio (NLR), one of the inflammatory parameters, is

found as a prognostic factor in several types of solid tumors, such as prostate cancer.

This study aims to assess whether there is a correlation between NLR with the results

of Gleason score of patients with prostate adenocarcinoma biopsy at Haji Adam Malik

Hospital Medan. A total of 121 patients underwent a prostate biopsy from early January

2013 - December 2015 at Adam Malik Hospital and 30 were not excluded. Data from

91 patients were then taken, including age, hematologic data pre biopsy, PSA on initial

examination, prostate weight estimation, and gleason score from biopsy results. The

data is processed with SPSS version 22. We found patients with a mean age of 68.34

years with an age ranging from 52 to 85 years. There is no significant correlation

between NLR and TBP with r = 0.077 and p = 0.469 and also there is no significant

correlation between NLR and PSA with r = 0.072 and p = 0.496. There is a significant

correlation between the ratio of neutrophils/lymphocytes with the results of gleason

score examination in prostate cancer patients at Haji Adam Malik Hospital. Further

studies are needed, whether the ratio of neutrophils / lymphocytes can be used to predict

the gleason score score in patients with suspected prostate cancer."

"Pendahuluan: Kanker prostat adalah keganasan terbanyak pada pria, penyebab kematian kedua terbesar akibat keganasan. Colok dubur adalah pemeriksaan dasar dan deteksi dini untuk mendiagnosis kanker prostat. Saat ini pemeriksaan Prostate-Specific Antigen (PSA) dianggap sebagai tumor marker yang paling bermanfaat untuk mendeteksi kanker prostat. The American Cancer Society dan American Urologic Association merekomendasikan penyaringan kanker prostat setiap tahun dengan pemeriksaan colok dubur dan PSA. Tujuan: Tujuan penelitian ini adalah untuk mengetahui hubungan antara pemeriksaan colok dubur dan nilai PSA pada pasien kanker prostat di RSUP DR Sardjito Yogyakarta periode Januari 2011 sampai Desember 2011. Metode Penelitian: Penelitian ini adalah kasus kontrol. Data dikumpulkan secara retrospektif dari catatan medis RSUP DR Sardjito pada pasien dengan colok dubur yang abnormal atau colok dubur normal dengan nilai PSA ≥ 10 ng/dl selama periode Januari 2011 sampai Desember 2011. Hasil pemeriksaan colok dubur dan nilai PSA didapatkan pada saat kunjungan pertama pasien ke rumah sakit. Analisis data nominal menggunakan Chi Square dengan SPSS 18. Hasil: Terdapat 87 pasien yang berhasil dikumpulkan selama periode Januari 2011 sampai Desember 2011 yang memiliki hasil pemeriksaan colok dubur abnormal atau colok dubur normal dengan nilai PSA ≥ 10 ng/dl. Pasien memiliki usia rata-rata 70 tahun, nilai median PSA 10,9 ng/dl. Pada pasien ini ditemukan colok dubur abnormal 43 (49,4%), colok dubur normal 44 (50,6%), PSA ≥ 10 ng/dl 69 (79,3%) dan PSA < 10 ng/dl 18 (20,7%). Pemeriksaan colok dubur dan PSA dinilai signifikan secara statistik untuk mendeteksi kanker prostat, hasil secara berurutan 67,2% vs 32,8% (p < 0,001) and 71,9% vs 28,1% (p = 0,002. Semua pasien dengan colok dubur abnormal dan PSA ≥ 10 ng/dl terdiagnosis kanker prostat (p < 0,001). Simpulan: Pemeriksaan colok dubur dan Prostate Specific Antigen (PSA) adalah prediktor terbaik untuk kanker prostat.

---

Introduction: Prostate cancer is the most frequent form of cancer in males, being also second cause of death by cancer. Digital Rectal Examination (DRE) is the basic examination and early diagnosis for prostate cancer. The Prostate-Specific Antigen (PSA) assay is currently considered the most useful tumor marker for detecting prostate cancer. Both the American Cancer Society and American Urologic Association recommended annual cancer screening with both Digital Rectal Examination (DRE) and PSA.

Objective: The objective of this study is to understand the correlation between DRE and PSA level in prostate cancer at Sardjito General Hospital Yogyakarta during januari 2011 until december 2011.

Research Method: This is a case control study. The data were retrospectively collected from medical record in sardjito general hospital who had abnormal DRE or normal DRE with PSA ≥ 10 ng/dl during januari 2011 until December 2011. The DRE and PSA value were examined in the first time they came to the hospital. A chi-square was performed to analyzed the nominal data with SPSS 18.

Result: There are 87 patients were collected during januari 2011 until December 2011 who had abnormal DRE or normal DRE with PSA ≥ 10 ng/dl. The median age was 70 years, median PSA level was 10,9 ng/dl. Of these patient, we found abnormal DRE in 43 (49,4%), normal DRE in 44 (50,6%), PSA ≥ 10 ng/dl was 69 (79,3%) and PSA < 10 ng/dl was 18 (20,7%). Digital Rectal Examination and PSA was statistically significant to detected prostate cancer, 67,2% vs 32,8% (p < 0,001) and 71,9% vs 28,1% (p = 0,002), respectively. All patient who had abnormal DRE and PSA ≥ 10 ng/dl were diagnosed with prostate cancer (p < 0,001).

Conclusion: Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) are the best predictor for prostate cancer. "

"Model prediksi kesintasan kanker prostat metastasis tulang sudah pernah dilakukan sebelumnya. Namun, model prediksi kesintasan kanker prostat metastasis tulang pra-terapi belum pernah dialukan sebelumnya. Tujuan penelitian ini adalah untuk menganalisis faktor-faktor klinis yang mempengaruhi ketahanan hidup (survival) pada kanker prostat dengan metastasis tulang serta mengembangkan nomogram prognostik ketahanan hidup pada pasien dengan kondisi tersebut. Terdapat 392 subyek dengan kanker prostat dengan metastasis tulang yang mendapat terapi Androgen Deprivation Therapy (ADT) dalam penelitian ini. Parameter pra-perawatan dianalisis menggunakan model cox-proportional untuk mengidentifikasi prediktor ketahanan hidup secara keseluruhan. Kovariat yang menunjukkan nilai signifikansi secara statistik pada analisis multivariat akan dipakai untuk membentuk nomogram. Model prediktor linier digunakan untuk mengembangkan nomogram. Nilai median ketahanan hidup keseluruhan adalah 40,3 bulan (95% CI: 32.2 - 48.5). Analisis univariat menunjukkan bahwa T-stage, Gleason Score, nilai antigen spesifik prostat inisial, dan jumlah lesi metastasis merupakan faktor-faktor prognostik independen terhadap angka ketahanan hidup keseluruhan. Semua prediktor ini tetap menunjukkan hasil yang signifikan secara statistik sebagai faktor prognostik independen pada analisis model multivariat cox-regression. Nomogram yang terbentuk dari faktor-faktor prediktor tersebut menunjukkan diskriminasi yan baik dalam memprediksi ketahanan hidup dalam 5 tahun dengan area under the curve (AUC) sebesar 0.69. Kesepakatan yang diterima dari probabilitas yang diamati dan diprediksi telah dinilai dalam plot kalibrasi. Nilai median ketahanan hidup keseluruhan adalah 40,3 bulan. Prediksi nomogram ini dapat berguna sebagai alat untuk memprediksi angka ketahanan hidup keseluruhan pada sebelum terapi kanker prostat metastasis, secara spesifik pada populasi Indonesia. Penelitian lebih lanjut dibutuhkan untuk memberikan validasi eksternal untuk mendukung penggunaan nomogram ini.

---

A survival prognostic model of prostate cancer with bone metastasis had been done before. However, a prognostic model of pre-treatment prostate cancer with bone metastasis had not yet done. This study aims to analyze the clinical factors among bone-metastatic prostate cancer and their relationships with survival as well as to develop a prognostic nomogram for overall survival in patients with this condition. This study included 392 patients with bone metastatic prostate caner treated with androgen deprivation therapy. Pre-treatment parameters were analyzed using cox-proportional hazard model to identify the predictors of overall survival. Covariates, which showed statistical significance on multivariate analysis, were used to develop a nomogram. Linear predictor model was utilized to develop the nomogram. Median overall survival was 40.3 months (95% CI: 32.2 to 48.5). Univariate analysis showed that clinical T-stage, Gleason Score, initial prostate specific antigen value, and number of metastatic lesion were independent prognostic factors for OS. These predictors still remained significant as independent prognostic factors for overall survival following analysis using multivariate cox-regression model. The nomogram constructed from those prognostic factors showed good discriminaton for predicting the 5-year OS with an Area Under the Curve of 0.69. Acceptable agreement of the observed and predicted probabilites was observed in the calibration plot. The median overall survival of patient with bone metastatic prostate cancer was 40.3 months. The prediction nomogram might be a useful tool for predicting overall survival in pre-treatment bone metastatic prostate cancer, specifically among Indonesian patients. Further studies are needed to provide external validation to support the utilization of this nomogram."

"Kanker payudara merupakan salah satu jenis kanker yang paling umum. Sebagaimana diketahui, kanker suatu jaringan dapat menyebar atau bermetastasis ke jaringan lain sebagai kanker sekunder, di mana pada kanker payudara 90% kematian selama pengobatan dikaitkan pada metastasis. Penelitian ini fokus kepada karakteristik metastasis bone only sebagai subtipe metastasis tulang kanker payudara yang belum banyak diteliti walaupun angka kelangsungan hidup (survival)nya paling bagus dibandingkan bila metastasis ke organ/tempat lainnya. Gambaran karakteristik pasien KPD BMO yg berobat di RSCM juga belum pernah diteliti. Penelitian ini menggunakan desain penelitian observasional deskriptif dengan desain studi cross sectional dengan teknik sampel total sampling. Terdapat 1278 pasien KPD metastasis yg berobat di RSCM 2017-2022. Didapatkan 148 pasien KPD BMO, namun karena ketidak lengkapan informasi di hasil pemeriksaan penunjang maka yang masuk kriteria inklusi penelitian ini adalah 47 pasien. Dari 47 pasien, ditemukan karakteristik 100% perempuan, rentang usia terbanyak 45-64 tahun (70,2%), 46,8% bersuku Jawa, 85,1% dalam usia menopause, dengan sebagian besar kanker karsinoma duktal invasif (85,1%) grade 2 (68,1%) dan subtipe luminal A (42,6%). Kasus Denovo sebanyak 48,9%. Ditemukan metastasis multiple (91,5%) lesi osteolitik(29,8%) , dan berlokasi di Os. Vertebrae (31,7%). Sejalan dengan penelitian sebelumnya dan faktor risiko metastasis bone only, sehingga dapat dilakukan studi lanjutan berupa studi analitik maupun genomic untuk mengkonfirmasi hubungan kausalitas tiap variabel.

---

Breast cancer is one of the most common types of cancer. As we know, cancer in one tissue can spread or metastasize to other tissues as secondary cancer, where in breast cancer 90% of deaths during treatment are attributed to these metastases. This study focuses on the characteristics of bone only metastases as a subtype of breast cancer bone metastases that has not been widely studied although its survival is better than breast cancer which metastases to other organs. This research uses a descriptive observational research design with a cross sectional study design with a total sampling technique. We found 1278 breast cancer with metastasis treated in RSCM within 2017-2022. There are 148 breast cancer bone metastasis only, but only 47 patients were included in the research due to the completed radiology data. Of the 47 patients, the characteristics of the 47 patients were 100% female; 70,2% aged 45-64 years-old ;46,8% Javanese ; 85,1% in menopausal age, 68,1% with grade 2 invasive ductal carcinoma and 42,6% luminal A subtype; 48,9% Denovo cases ; 91,5% suffered from Multiple osteolytic lesion metastases and 31,7% were located in Os. Vertebrae. In line with previous research and risk factors for bone only metastasis, further studies can be carried out in the form of analytical or genomic studies to confirm the causal relationship between each variable."

"Pendahuluan: Metastatic Bone Disease (MBD) merupakan tempat penyebaran jauh terbanyak ketiga setelah paru dan liver. Hal ini menimbulkan morbiditas yang tidak sedikit dan pada akhirnya memengaruhi kualitas hidup dan kesintasan pasien. Metode: Penelitian ini menggunakan studi potong lintang di RSUPN Cipto Mangunkusumo dengan total sampling. Pasien yang terdiagnosis MBD selama periode 2008 – 2018 dilihat karakteristik, kesintasan, dan jika masih hidup, dilakukan penghitungan skor fungsional menggunakan kuesioner SF-36 dan MSTS. Hasil: Terdapat 113 pasien MBD dengan rerata usia 54,34 ± 11,09, 69% perempuan, 24,8% tumor primer dari paru, 17,7% dari mammae, 16,8% dari tiroid. 55,8% lesi MBD terdapat pada ekstremitas dan 74,3% merupakan lesi soliter. 65,5% pasien tidak menjalani operasi, namun 78,8% mendapatkan bisfosfonat dan 51,3% mendapatkan radioterapi. Sebanyak 82,3% pasien sudah meninggal, sehingga terdapat 20 pasien yang masih hidup. SF-36 menunjukkan rentang median 40,0 – 100,0 dari 8 skala yang ada. MSTS ekstremitas atas rerata 45,55 ± 24,46 dan ekstremitas bawah median 26,67 (20,00 – 60,00). Analisis bivariat menunjukkan hubungan antara pembedahan dengan kesintasan (P=0,034). Analisis multivariat menunjukkan operasi memiliki peluang terhadap kesintasan yang lebih baik sebesar 2,8 kali (95%CI 1,1 – 7,6). Kesimpulan: Operasi memiliki hubungan yang bermakna terhadap kesintasan pasien MBD.

---

Introduction: Metastatic Bone Disease (MBD) is the third distant sites after lungs and liver. This creates quite morbidity and in the end affect the patient’s quality of life and survival. Methods: This study uses cross sectional design with total sampling at Cipto Mangunkusumo Hospital. MBD diagnosed patient during 2008 – 2018 were evaluated for characteristics, survival rate. Survived patient will evaluated for functional score with SF-36 and MSTS. Results: From 113 patients, with mean age of 54,34 ± 11,09, 69% were female, 24,8% were lung primary tumor, 17,7% from breast tumor, and 16,8% from thyroid tumor. 55,8% of the lesions were from extremity and 74,3% were solitary lesions. 65,5% patients did not get a surgery, 78,8% were given bisphosphonates, and 51,3% got a radiotherapy treatment. 82,3% patients were already died, so we got 20 patients that were still alive and being evaluated for the functional score. SF-36 shows median of 40,0 – 100,0 from 8 scales, and upper extremity MSTS results mean 45,55 ± 24,46, and lower extremity MSTS results median 26,67 (20,00 – 60,00). Bivariate analysis shows statistically significant association of surgery with survival (P=0,034). Multivariate analysis shows surgery has a 2,8 times higher chance of survival (95%CI 1,1 – 7,6). Conclusion: Surgery has a significant association with MBD patient survival."